CD38-directed Antibody Interactions [MoA] class drugs

3 results

  • darzalex - daratumumab injection, solution, concentrate

    (Daratumumab)
    Janssen Biotech, Inc.
    DARZALEX treats multiple myeloma in adults — used in newly diagnosed patients ineligible or eligible for stem cell transplant, and in relapsed/refractory cases after one or more prior therapies, as part of various combination regimens or as monotherapy.
    Medication Details
    Drug Interactions

  • darzalex faspro - daratumumab and hyaluronidase - fihj

    (Daratumumab And Hyaluronidase-Fihj (Human Recombinant))
    Janssen Biotech, Inc.
    DARZALEX FASPRO treats adult patients with multiple myeloma (newly diagnosed or relapsed/refractory, across various combination regimens), high-risk smoldering multiple myeloma, and newly diagnosed light chain (AL) amyloidosis. Not recommended for AL amyloidosis with NYHA Class IIIB/IV cardiac disease outside clinical trials.
    Medication Details
    Drug Interactions

  • sarclisa - isatuximab injection, solution, concentrate

    (Isatuximab)
    Sanofi-Aventis U.S. Llc
    Sarclisa treats adults with multiple myeloma in three combination regimens: with pomalidomide and dexamethasone after ≥2 prior therapies; with carfilzomib and dexamethasone for relapsed or refractory disease after 1–3 prior lines; and with bortezomib, lenalidomide, and dexamethasone for newly diagnosed patients ineligible for stem cell transplant.
    Medication Details
    Drug Interactions